Table 4.
Nonmyeloablative/RIC Conditioning Regimen in Patients With SCD.
| No. | Age range (years) | Graft source | Donor | Conditioning regimen | GvHD prophylaxis | Acute GvHD (grade II–IV) | Chronic GvHD | OS % | EFS % | |
|---|---|---|---|---|---|---|---|---|---|---|
| Hsieh et al. 37 | 30 | 17–65 | PB | MRD | NMA: Alemtuzumab+TBI |
Sirolimus | No | No | 97% | 87% |
| Saraf et al. 35 | 13 | 17–40 | PB | MRD | NMA: Alemtuzumab+TBI |
Sirolimus | No | No | 100% | 92% |
| Al-Zahrani et al. 36 | 18 | 14–39 | PB | MRD | NMA: Alemtuzumab+TBI |
Sirolimus | No | No | 100% | 88.9% |
| Ozdogu et al. 31 | 20 | 20–45 | PB | MRD | NMA: Flu+CY+BU+TBI+ATG |
Sirolimus | 5% | No | 100% | 100% |
| Alzahrani et al. 38 | 110 | 14–43 | PB | MRD | NMA: Alemtuzumab+TBI |
Sirolimus | skin grade I–II in 3 patients | NO | 97% | 87.3% |
| Krishnamurti et al. 33 | 7 | 6–18 | BM | MSD | RIC: BU(2)+Flu+ATG+TLI |
CSA+MMF | Skin grade II in 1 patient | Limited skin in 1 patient | 100% | 86% |
Alk: alkeran(melphalan); ATG: anti-thymocyte globulin; BM: bone marrow; BU: busulfan; CSA: cyclosporine; CY: cyclophosphamide; EFS: event-free survival; Flu: fludarabine; GvHD: graft versus host disease; NMA: nonmyeloablative conditioning; MMF: mycophenolate mofetil; MRD: matched related donor; MSD: matched sibling donor; OS: overall survival; PB: peripheral blood; RIC: reduced intensity conditioning; TBI: total body irradiation; TLI: total lymphoid irradiation.